Market News How it works Learn FAQ
| RCT 0.1111 45.99% | NU 12.415 -18.11% | EWZ 33.695 -20.89% | TGL 0.245 10.61% | BBD 2.875 -29.36% | AZTR 1.75 144.76% | SRTM 0.3361 -21.89% | ITUB 7.655 -20.84% | NVD 3.991 -4.75% | XP 15.635 -48.59% | SHFS 0.0996 -24.77% | SOXL 92.26 10.41% | SPCX 148.545 0.72% | PBR 22.22 -15.06% | CLRO 4.77 46.77% | VALE 11.94 -3.71% | GCDT 0.1424 -19.14% | INTC 91.4822 5.20% | NWGL 0.0865 5.49% | TSLL 10.955 12.24% | CRWV 56.965 5.03% | NVDA 216.08 2.43% | SOXS 47.02 -10.37% | BITO 10.715 -1.06% | NOK 8.7457 7.44% | SGRY 23.2124 47.38% | GPUS 0.1839 8.88% | RWM 14.465 -0.58% | TSLG 5.4768 12.46% | ABEV 2.805 -15.00% | IREN 26.31 5.64% | RBNE 0.1704 -10.32% | JBLU 2.305 -12.19% | INTR 4.505 -37.34% | TQQQ 68.81 3.80% | SPDN 8.485 -0.64% | SBS 4.595 -28.20% | AAL 12.24 1.07% | QID 14.175 -2.58% | TSLA 395.14 6.16% | LUCD 0.5264 28.08% | XTND 2.0901 18.08% | SPRC 1.4801 35.79% | WULF 12.38 9.36% | NFLX 63.145 -4.11% | SID 0.9294 -21.24% | CIFR 7.995 0.69% | SQQQ 38.17 -3.81% | T 21 0.33% | PBR-A 19.54 -16.96%
HRHeron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX)

NASDAQ Capital Market · Currency in USD
$0.30 ▼ 0.00 (-0.20%)
As of Oct 26, 2:16 PM ET. Market open.

Summary

Previous Close
$0.30
Open
$0.30
Day's Range
$0.28 – $0.30
52 Week Range
$0.26 – $1.58
Volume
720,103
Avg. Volume
2,685,906
Market Cap
$57.37M
Beta (5Y Monthly)
1.63
PE Ratio (TTM)
--
EPS (TTM)
-$0.18
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.67

Profile: Heron Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
128
CEO
Craig Alexander Collard

Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.03 · Revenue est. $37.50M
DateEst.Actual
Aug 10, 2026-$0.01-$0.03Miss
May 11, 2026-$0.03-$0.04Miss
Feb 26, 2026-$0.03-$0.02Beat
Nov 4, 2025-$0.01-$0.05Miss
Aug 8, 2025-$0.01-$0.02Miss
May 6, 2025-$0.01$0.01Beat

Analyst view

Consensus price target
$6.67 ▲ +2,107.1%
Range $5.00 – $9.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Get free alerts on HRTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.